Compare AJANTA PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA GLENMARK PHARMA AJANTA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.0 14.6 170.9% View Chart
P/BV x 6.9 2.4 289.1% View Chart
Dividend Yield % 0.5 0.4 121.1%  

Financials

 AJANTA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
AJANTA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422712 199.8%   
Low Rs898484 185.6%   
Sales per share (Unadj.) Rs233.5349.6 66.8%  
Earnings per share (Unadj.) Rs44.032.8 134.1%  
Cash flow per share (Unadj.) Rs52.244.3 117.6%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.3 231.9%  
Book value per share (Unadj.) Rs255.1198.6 128.4%  
Shares outstanding (eoy) m88.02282.17 31.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.01.7 290.6%   
Avg P/E ratio x26.418.2 144.7%  
P/CF ratio (eoy) x22.213.5 165.0%  
Price / Book Value ratio x4.53.0 151.1%  
Dividend payout %20.56.1 335.5%   
Avg Mkt Cap Rs m102,081168,625 60.5%   
No. of employees `0006.812.0 56.5%   
Total wages/salary Rs m4,30720,561 20.9%   
Avg. sales/employee Rs Th3,022.68,196.0 36.9%   
Avg. wages/employee Rs Th633.41,708.1 37.1%   
Avg. net profit/employee Rs Th569.1768.5 74.1%   
INCOME DATA
Net Sales Rs m20,55498,655 20.8%  
Other income Rs m2112,081 10.1%   
Total revenues Rs m20,765100,736 20.6%   
Gross profit Rs m5,66415,858 35.7%  
Depreciation Rs m7213,259 22.1%   
Interest Rs m123,346 0.3%   
Profit before tax Rs m5,14311,335 45.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1,2733,756 33.9%   
Profit after tax Rs m3,8709,250 41.8%  
Gross profit margin %27.616.1 171.4%  
Effective tax rate %24.833.1 74.7%   
Net profit margin %18.89.4 200.8%  
BALANCE SHEET DATA
Current assets Rs m11,81266,968 17.6%   
Current liabilities Rs m3,77640,211 9.4%   
Net working cap to sales %39.127.1 144.2%  
Current ratio x3.11.7 187.8%  
Inventory Days Days7783 92.9%  
Debtors Days Days8281 100.5%  
Net fixed assets Rs m14,39833,322 43.2%   
Share capital Rs m175282 62.2%   
"Free" reserves Rs m22,27755,770 39.9%   
Net worth Rs m22,45256,052 40.1%   
Long term debt Rs m735,738 0.0%   
Total assets Rs m26,962132,888 20.3%  
Interest coverage x444.34.4 10,127.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.7 102.7%   
Return on assets %14.49.5 151.9%  
Return on equity %17.216.5 104.4%  
Return on capital %23.017.8 128.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68262,998 17.0%   
Fx outflow Rs m2,10222,859 9.2%   
Net fx Rs m8,58040,140 21.4%   
CASH FLOW
From Operations Rs m3,74813,242 28.3%  
From Investments Rs m-2,228-6,990 31.9%  
From Financial Activity Rs m-1,475-7,387 20.0%  
Net Cashflow Rs m45-2,971 -1.5%  

Share Holding

Indian Promoters % 73.8 48.3 152.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 6.9 22.5%  
FIIs % 7.6 34.4 22.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 56,727 37.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  SUVEN LIFE SCIENCES  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)

Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Mar 3, 2021 11:52 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - NEULAND LABS COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS